Nu Skin Enterprises Inc. (NYSE:NUS) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.78 and last traded at $52.48, with a volume of 291,681 shares traded. The stock had previously closed at $51.96.

A number of research analysts have issued reports on NUS shares. Citigroup Inc. restated a “buy” rating and set a $45.00 target price (up previously from $38.00) on shares of Nu Skin Enterprises in a research report on Tuesday, April 19th. Zacks Investment Research upgraded shares of Nu Skin Enterprises from a “strong sell” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Thursday, April 14th. Deutsche Bank AG restated a “hold” rating and set a $55.00 target price (up previously from $45.00) on shares of Nu Skin Enterprises in a research report on Sunday. Pivotal Research increased their target price on shares of Nu Skin Enterprises from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, June 16th. Finally, Jefferies Group restated a “hold” rating and set a $41.00 target price on shares of Nu Skin Enterprises in a research report on Friday, June 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $45.22.

The firm’s 50 day moving average price is $46.77 and its 200 day moving average price is $38.51. The company has a market cap of $2.93 billion and a PE ratio of 30.392.

Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings data on Thursday, April 28th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.37 by $0.05. The company earned $471.80 million during the quarter, compared to the consensus estimate of $465.08 million. The business’s revenue was down 11.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.60 EPS. Equities research analysts expect that Nu Skin Enterprises Inc. will post $2.79 EPS for the current fiscal year.

Several hedge funds have bought and sold shares of NUS. California Public Employees Retirement System raised its stake in Nu Skin Enterprises by 10.7% in the fourth quarter. California Public Employees Retirement System now owns 158,400 shares of the company’s stock valued at $6,002,000 after buying an additional 15,300 shares during the period. New York State Common Retirement Fund raised its stake in Nu Skin Enterprises by 11.2% in the fourth quarter. New York State Common Retirement Fund now owns 241,115 shares of the company’s stock valued at $9,136,000 after buying an additional 24,212 shares during the period. Boston Partners raised its stake in Nu Skin Enterprises by 4.7% in the fourth quarter. Boston Partners now owns 482,826 shares of the company’s stock valued at $18,294,000 after buying an additional 21,613 shares during the period. Twin Capital Management Inc. acquired a new stake in Nu Skin Enterprises during the fourth quarter valued at about $1,564,000. Finally, Bank of Montreal Can raised its stake in Nu Skin Enterprises by 826.4% in the fourth quarter. Bank of Montreal Can now owns 106,790 shares of the company’s stock valued at $4,047,000 after buying an additional 95,263 shares during the period.

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care system and ageLOC Tru Face Essence Ultra anti-aging skin care serum.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.